Related references
Note: Only part of the references are listed.Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
IL-23 in inflammatory bowel diseases and colon cancer
Markus F. Neurath
CYTOKINE & GROWTH FACTOR REVIEWS (2019)
Can IL-23 be a good target for ulcerative colitis?
Mariangela Allocca et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)
Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study
Levente Parragi et al.
JOURNAL OF CROHNS & COLITIS (2018)
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
Timo Rath et al.
FRONTIERS IN IMMUNOLOGY (2018)
Ulcerative Colitis: Are We Neglecting Its Progressive Character
Paulo Massinha et al.
GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY (2018)
Malignancies and ustekinumab: an analysis of the US Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database
A. G. Florek et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Immunopathogenesis of IBD: current state of the art
Heitor S. P. de Souza et al.
Nature Reviews Gastroenterology & Hepatology (2015)
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study
M. Chaparro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease
Alessandra Geremia et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
MEDICAL PROGRESS Ulcerative Colitis
Silvio Danese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
InterIeukin-23/Th17 Pathways and Inflammatory Bowel Disease
Clara Abraham et al.
INFLAMMATORY BOWEL DISEASES (2009)
Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation
Melanie A. Kleinschek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice
Charles O. Elson et al.
GASTROENTEROLOGY (2007)
Interleukin-23 drives innate and T cell-mediated intestinal inflammation
Sophie Hue et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6
D Yen et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Share Paper
